305 completed, 51 terminated, 30 recruiting, 23 unknown. 450 Phase 2, 60 Phase 1, 53 Phase 3.
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis Cannabidiol (CBD), Placebo - Schizophrenia Spectrum Disorders, Cannabis Use | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2050-01-01 | 2021-04-19 | |
| Brain Imaging of DSP-2342 DSP-2342 - SCHIZOPHRENIA 1 (Disorder) | Phase 2 | Not yet recruiting | Johns Hopkins University | 20 | 2027-01-01 | 2026-09-30 |
| Xingqi Daozhi Decoction for Antipsychotic-Induced Constipation Xingqi Daozhi Decoction, Placebo Group - Schizophrenia, Antipsychotic Drug | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Mental Health Center | 46 | 2026-10-01 | 2026-08-17 |
| A Cognitive Mobile Intervention for Motivation in Psychotic Disorders Cognitive Training, Mobile cognitive training - Schizophrenia / Schizoaffective Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 45 | 2026-09-01 | 2026-06-30 |
| Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia Deferiprone (DFP), N-Acetyl Cysteine (NAC) - Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder | Phase 2 | Recruiting | Amit Lotan | 80 | 2026-08-12 | 2026-09-29 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophrenia Brexpiprazole for ER injection, 45 mg, Brexpiprazole for ER injection, 100 mg - Schizophrenia | Phase 2 / Phase 3 | Not yet recruiting | Bostal Drug Delivery Co., Ltd | 16 | 2026-08-01 | 2026-08-03 |
| A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia 30 mg B2227, 70 mg B2227, 150 mg B2227 - Schizophrenia | Phase 2 / Phase 3 | Not yet recruiting | Bostal Drug Delivery Co., Ltd | 84 | 2026-08-01 | 2026-07-23 |
| A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398 SIPI6398 Tablets - Schizophrenia Disorder | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Zhongze Therapeutics Co., Ltd. | 9 | 2026-08-01 | 2026-06-04 |
| Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults VV119 2mg, VV119 4mg, VV119 6mg - Schizophrenia | Phase 2 | Not yet recruiting | Vigonvita Life Sciences | 500 | 2026-07-31 | 2026-07-15 |
| Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia Ublituximab - Schizophrenia | Phase 2 | Recruiting | TG Therapeutics, Inc. | 60 | 2026-07-27 | 2026-10-30 |
| No Guts No Glory Probiotics Probiotic Formula, Placebo - Patients Using Olanzapine, Quetiapine, Risperidone or Clozapine | Phase 2 / Phase 3 | Recruiting | University Medical Center Groningen | 112 | 2026-06-01 | 2026-05-26 |
| Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life Study Ecological Momentary Assessment (EMA) and Reality Monitoring tasks - Schizophrenia | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Charles Perrens, Bordeaux | 120 | 2026-06-01 | 2026-03-16 |
| Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia EEG Neurofeedback - SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder | Phase 2 | Not yet recruiting | University of California, San Diego | 104 | 2026-06-01 | 2026-05-18 |
| A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia ML-007C-MA - Schizophrenia | Phase 2 | Recruiting | MapLight Therapeutics | 500 | 2026-03-31 | 2026-10-15 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia LY03020, Placebo - Schizophrenia | Phase 2 | Not yet recruiting | Luye Pharma Group Ltd. | 160 | 2026-03-31 | 2026-02-09 |
| Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia GXV813, Placebo - Schizophrenia | Phase 2 | Recruiting | Novartis Pharmaceuticals | 142 | 2026-03-16 | 2026-07-29 |
| Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia NBI-1117570, Placebo - Schizophrenia | Phase 2 | Recruiting | Neurocrine Biosciences | 120 | 2026-02-16 | 2026-07-22 |
| A Study of Brenipatide in Adult Participants With Schizophrenia Brenipatide, Placebo - Schizophrenia | Phase 2 | Recruiting | Eli Lilly and Company | 450 | 2026-02-10 | 2026-10-07 |
| Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone Risperidone 4mg/day, Ashwagandha, Placebo - Schizophrenia Patients, Neuroinflammation | Phase 2 | Completed | Hasanuddin University | 80 | 2025-10-01 | 2026-05-12 |
| Sex Differences in NMDA-enhancing Treatment of Schizophrenia NMDAE, Placebo Cap - Schizophrenia | Phase 2 | Recruiting | China Medical University Hospital | 90 | 2025-09-16 | 2025-09-17 |
Showing 20 of 450. Sign in to see all of them.
Psychotic Disorders (124) · Mental Disorders (31) · Cognitive Dysfunction (15) · Bipolar Disorder (14) · Hallucinations (11) · Schizophrenia Spectrum and Other Psychotic Disorders (10) · Inflammation (9) · Obesity (7) · Tobacco Use Disorder (7) · Cognition Disorders (6) · Depression (6) · Depressive Disorder, Major (6) · Schizophrenia, Treatment-Resistant (6) · Smoking (6)
Schizophrenia Spectrum and Other Psychotic Disorders (440) · Mental Disorders (419) · Pathological Conditions, Signs and Symptoms (45) · Behavior (34) · Signs and Symptoms (33) · Nervous System Diseases (27) · Neurocognitive Disorders (22) · Neurologic Manifestations (21) · Chemically-Induced Disorders (19) · Substance-Related Disorders (17) · Neurobehavioral Manifestations (16) · Cognition Disorders (15) · Mood Disorders (15) · Nutritional and Metabolic Diseases (15) · Behavioral Symptoms (14)
Risperidone (35) · Olanzapine (25) · Aripiprazole (20) · Cannabidiol (8) · ziprasidone (8) · LY 2140023 (7) · Oxytocin (7) · Paliperidone Palmitate (7) · Quetiapine Fumarate (7) · Lurasidone Hydrochloride (6) · Sugars (6) · Transcranial Direct Current Stimulation (6) · cariprazine (6) · Galantamine (5) · Sarcosine (5)
China Medical University Hospital (14) · Yale University (12) · Otsuka Pharmaceutical Development & Commercialization, Inc. (11) · University of Maryland, Baltimore (10) · Merck Sharp & Dohme LLC (8) · Nathan Kline Institute for Psychiatric Research (8) · Pfizer (8) · Denovo Biopharma LLC (7) · University of California, San Diego (7) · H. Lundbeck A/S (6) · New York State Psychiatric Institute (6) · Novartis Pharmaceuticals (6) · Tanabe Pharma Corporation (6) · VA Office of Research and Development (6) · AbbVie (5)
United States (261) · Taiwan (35) · Russia (26) · Japan (24) · Canada (23) · Germany (23) · Ukraine (22) · Bulgaria (19) · Poland (17) · China (15) · India (15) · Romania (15) · Israel (14) · France (13) · Spain (13)
Alan Breier, MD (4) · F. Markus Leweke, MD (4) · Robert Freedman, MD (4) · Scott W Woods, MD (4) · Daniel C Javitt, MD, PhD (3)
PMID 28433500, PMID 25890643, PMID 33854317, PMID 34091867, PMID 36369028, PMID 22992330, PMID 26879587, PMID 27188270, PMID 27319970, PMID 27789188, PMID 28318835, PMID 28692485, PMID 32141724, PMID 35704951, PMID 37142273, PMID 37230961, PMID 38085556, PMID 10473315, PMID 11483142, PMID 12823166, PMID 15870612, PMID 15936729, PMID 16095473, PMID 16131943, PMID 16571581, PMID 16680620, PMID 16737798, PMID 17284138, PMID 17355521, PMID 17487227, PMID 17659263, PMID 17690599, PMID 17898352, PMID 18096137, PMID 18381905, PMID 18584319, PMID 18678800, PMID 18923067, PMID 19497249, PMID 19818257, PMID 19887019, PMID 19941696, PMID 20435443, PMID 20728875, PMID 20810586, PMID 20816042, PMID 21145041, PMID 21294997, PMID 21303566, PMID 21346607
2016 (4), 2017 (4), P50MH082999 (4), 2019 (3), 2008 (2), 1DP5OD036172-01 (1), 2018 (1), 2025 (1), I01CX001414 (1), I01CX001761 (1), P50MH086383 (1), P50MH103222 (1), R01DA024674 (1), R01MH059807 (1), R01MH060390 (1)